Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“Review from ASCO26 – LCSM Developmental Therapeutics Rapid Oral.
177Lu-DOTATATE (SSTR2-Targeted RLT) and SOC as 1L ES-SCLC.
RD determined: 7.4 GBq; no DLTs in 17 evaluable patients.
93.1% completed induction; safety consistent with known profile.”
Title: Phase Ib results from the phase Ib/II study of [177Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for patients with extensive-stage small cell lung cancer.
Author: Stephen Liu
Other articles featuring Hidehito Horinouchi on OncoDaily.
